Pfizer has announced top-line results from a second Phase 3 study evaluating the efficacy and safety of its oral JAK1 inhibitor, abrocitinib, in patients aged 12 or over with moderate to severe atopic dermatitis.
The study, called JADE MONO-2, used 391 subjects and was designed to evaluate the efficacy and safety of two doses (100mg and 200mg once daily) of abrocitinib monotherapy over the course of 12 weeks.
